The ELMT IPO Filing: A 97-Year-Old Tungsten Maker Goes Public at a Complicated Moment

The Elmet Group Co. launched its IPO roadshow today, offering approximately 7.7 million shares at an expected price of $12 to $14 per share on the Nasdaq Capital Market under the ticker ELMT. At the midpoint, the company would raise roughly $100 million in gross proceeds.

This is not a speculative tech debut. The Elmet Group is a 97-year-old, Portland, Maine-based manufacturer of precision-engineered tungsten and molybdenum components and high-power microwave systems. Its products serve aerospace, defense, semiconductor, medical, and energy end markets. The company is the only U.S.-owned, fully integrated producer of engineered pure tungsten and molybdenum products, a distinction that carries real national security weight in a world where China dominates roughly 80% of global tungsten supply.

Revenue reached $201.6 million for fiscal year 2025, up 6% year over year. But net income collapsed 64%, falling from $15.4 million to $5.5 million despite the top-line growth. That gap between the revenue story and the profitability story is the central tension in this filing, and it deserves a closer look before anyone chases the defense narrative.

Quick answer: ELMT is expected to price the week of April 20, 2026 and begin trading on the Nasdaq on April 23 at $12 to $14 per share, with 7.69 million shares offered for a target raise of roughly $100 million. At the $13 midpoint, the fully-diluted market cap works out to approximately $364 million on 27.97 million shares outstanding.

In our view, the setup is balanced. The defense supply chain narrative is genuine and the $240M to $360M implied enterprise value looks modest against defense peers, but the 64% net income decline and concentrated customer base argue for patience rather than a chase.

ELMT IPO Date and Pricing

ELMT is scheduled to begin trading on the Nasdaq Capital Market on Thursday, April 23, 2026, following pricing the night before. The table below summarizes the deal terms as disclosed in the company’s S-1 filing and launch announcement.

Item	Detail
Ticker	ELMT
Exchange	Nasdaq Capital Market
Expected IPO date	April 23, 2026
Price range	$12.00 to $14.00
Shares offered	7.69 million primary, plus 1.2M greenshoe
Target raise	Approximately $100 million (gross)
Shares outstanding post-IPO	27.97 million (fully diluted)
Fully-diluted valuation at $13 midpoint	Approximately $363.6 million
Underwriters	Cantor Fitzgerald (lead), Needham & Co., Canaccord Genuity, Roth Capital
Use of proceeds	Majority to acquisition-related debt repayment; balance for capacity expansion and working capital
First-day performance	Pending (had not traded as of publication)

The math is straightforward. Multiply the $13 midpoint by the 27.97 million post-IPO share count disclosed on stockanalysis.com and the implied fully-diluted market capitalization lands near $363.6 million. At $12 per share the figure drops to roughly $335.6 million; at $14 it rises to about $391.6 million. Backing out the roughly $90 million in net proceeds and netting against remaining balance-sheet debt produces an enterprise value in the $240 million to $360 million range that external analysts have cited, or about 10x to 15x estimated $24 million EBITDA.

ELMT IPO Prediction

We believe ELMT’s debut is likely to be a modest positive, not a breakout. Our view hedges in both directions because the setup contains real strategic scarcity and real financial friction at the same time.

The bull case rests on three drivers. First, China controls roughly 80% of global tungsten production, and ELMT is the only U.S.-owned, fully integrated producer of engineered tungsten and molybdenum at scale. Second, the company’s components are embedded in more than 100 U.S. defense programs, which anchors revenue to a spending category that is supported by appropriated, not discretionary, budget. Third, peer reference points cut favorably. MP Materials trades near a $10 billion market cap on rare earths with DoD backing, and Fireweed Metals, a Canadian tungsten developer, reached roughly $717 million on a single project without revenue, which puts ELMT’s $364 million fully-diluted tag in visible context for investors shopping the reshoring theme.

The bear case is also specific. Net income fell 64% year over year to $5.5 million while revenue grew, and a trailing P/E near 83x leaves little cushion if margin recovery stalls. Use of proceeds tilts toward acquisition debt repayment rather than growth capital, which limits the story’s near-term capacity narrative. The 2026 IPO market is also crowded with mega-listings like SpaceX and OpenAI, which may pull generalist attention away from a sub-$400 million specialty industrial.

Our base case has ELMT trading roughly flat to plus-15% above its offer price over the first 90 days, conditional on first post-IPO earnings validating a path back toward a mid-teens EBITDA margin. A bullish path to plus-25% or more could emerge if the company discloses new DoD supply agreements or the critical-minerals policy environment tightens further. A bearish path to minus-10% or worse is on the table if gross margin compression persists and the backlog fails to convert to profitable revenue. The first dated catalyst to watch is ELMT’s inaugural post-IPO quarterly earnings release, likely in August 2026, where management will need to show that the 64% net income decline was integration-driven rather than structural.

The National Security Angle: Why Tungsten Matters

Refractory metals are materials with extremely high melting points: tungsten, molybdenum, niobium. They survive temperatures that would destroy conventional alloys. That property makes them essential in jet engine components, missile guidance systems, semiconductor manufacturing equipment, and directed energy weapons.

China controls approximately 80% of global tungsten production. That concentration is not theoretical risk. It is a bottleneck the U.S. Department of Defense has flagged repeatedly in supply chain reviews.

In November 2023, Elmet Technologies acquired H.C. Starck Solutions Americas, consolidating its position as the largest domestic producer. The deal added facilities in Ohio and Michigan to Elmet’s existing Maine plant, bringing total manufacturing space to over 500,000 square feet and the workforce to approximately 538 employees.

The company’s products are embedded in over 100 U.S. defense programs. Its Engineered Microwave Products (EMP) segment manufactures high-power microwave systems used in directed energy weapons, radar, and electronic warfare, areas where the U.S. military is actively expanding investment. It sits at the intersection of defense modernization and supply chain reshoring, two of the most durable spending trends in federal policy.

The Numbers: Revenue Growth With a Profitability Problem

Here is what the filing shows.

Metric	FY 2024	FY 2025	Change
Revenue	$190.3M	$201.6M	+5.9%
Net Income	$15.4M	$5.5M	-64.3%
EBITDA Margin (est.)	~15%	~12%	Compressed
CMC + EMP Backlog Growth	N/A	+$26.3M YoY	+37.6%

Source: Seeking Alpha, ainvest, Renaissance Capital

The top line looks healthy. Revenue grew nearly 6%, and the combined backlog across both business segments surged 37.6% year over year as of December 31, 2025. That backlog growth substantially outpaces revenue growth, which suggests future revenue visibility is improving.

The bottom line tells a different story. Net income fell from $15.4 million to $5.5 million, a 64% decline on a growing revenue base. EBITDA margin compressed to roughly 12%.

The filing does not isolate a single cause, but the most likely contributors are integration costs from the H.C. Starck acquisition, raw material pricing pressure, and contract structures that lag cost increases. Investors should expect management to address margin recovery on the roadshow. If they do not, that is a red flag.

The backlog is the counterargument. A 37.6% increase in committed orders suggests that demand is accelerating even as margins compress. The question is whether that demand converts to profitable revenue or just higher-cost volume.

IPO Details and Use of Proceeds

The offering is straightforward: 7.7 million shares at $12 to $14, with underwriters holding a 30-day option for up to 1.2 million additional shares. Cantor Fitzgerald is lead book-runner, with Needham & Company and Canaccord Genuity as joint book-runners and Roth Capital Partners as co-manager. The underwriter lineup skews toward mid-cap specialty banks with defense and industrials expertise, consistent with the offering’s modest size.

Here is the part that matters most: the majority of proceeds are earmarked for debt repayment, including the Great Falls Term Loan, the President Line of Credit, and the AAI Note. These are acquisition-related obligations from the H.C. Starck deal. Remaining funds go toward a new tungsten sphere and cube fragmentation line, potential complementary acquisitions, working capital, and general corporate purposes.

This is not an IPO funding a growth moonshot. It is an IPO funding a balance sheet cleanup. Deleveraging after a strategic acquisition is rational, but investors should understand they are funding debt retirement first and capacity expansion second.

How ELMT Fits Into the 2026 IPO Market

The 2026 IPO calendar is dominated by scale. SpaceX plans a June roadshow targeting a $75 billion raise, with up to 30% reserved for retail investors. As we discussed in our SpaceX IPO analysis, the mega-listings will dominate headlines.

OpenAI is eyeing a Q4 listing at a potential $1 trillion valuation. In defense industrials, KNDS is planning a dual listing in Paris and Frankfurt at approximately 20 billion euros.

ELMT’s $100 million offering is small by comparison. That could mean less attention from generalist investors, but it could also mean less competition for the specific defense-industrial allocation base that follows critical materials and reshoring themes.

At an implied EV/EBITDA of 10x to 15x, the valuation appears modest relative to defense peers. Using approximately $24 million in estimated EBITDA, the implied enterprise value ranges from $240 million to $360 million.

That discount reflects the margin compression risk. If margins recover, the current pricing looks reasonable. If they do not, the multiple is fair.

What to Watch

Three things matter for anyone evaluating this filing.

First, margin recovery trajectory. The first post-IPO earnings report will show whether the 64% net income decline was a transitory integration cost or a structural profitability problem. Management guidance on the roadshow will offer the first signal.

Second, backlog conversion. A 37.6% backlog increase means nothing if it does not translate to revenue acceleration and, more importantly, profitable revenue. Watch the book-to-bill ratio in coming quarters.

Third, debt reduction pace. If IPO proceeds retire the acquisition debt on schedule, the balance sheet improves quickly. If management diverts funds to other uses, the leverage story drags.

The strategic value here is genuine. Elmet is the sole U.S.-owned, vertically integrated producer of tungsten and molybdenum at scale, operating in a market where the global refractory metals industry is projected to grow at 3.9% annually. Its products sit inside more than 100 defense programs.

The defense supply chain reshoring trend is not a narrative; it is appropriated budget. For a broader look at how to evaluate concentrated positions and sector-specific exposure, see our guide to diversification.

This is a filing analysis, not a recommendation. The numbers, the risks, and the strategic context are here. The decision is yours.

---

Ferrante Capital LLC is a registered investment adviser. Information presented is for educational purposes only and does not constitute investment advice, a solicitation, or a recommendation to buy or sell any security. All investing involves risk, including the possible loss of principal.

FC and its principals may hold positions in ELMT. This analysis is for educational purposes only and does not constitute a recommendation to buy, sell, or hold any security.

Forward-looking statements reflect Ferrante Capital’s current analysis and involve assumptions and estimates. Actual results may differ materially. Past performance is not indicative of future results.

Please consult a qualified financial professional before making investment decisions.